Press Release – HEBEI CHANGSHAN BIOCHEM PHARMA AND ALBUMEDIX ENTER INTO AGREEMENT FOR DEVELOPMENT OF PATIENT-FRIENDLY TYPE II DIABETES TREATMENT

17 May 2016

 Albumedix™ Albumin-Based Half-Life Extension Technology Used In Clinical Development Of Hebei Changshan Biochem Pharma’s Once-Weekly Diabetes Treatment For The Chinese Market

Copenhagen, Denmark, Shijiazhuang, China and Los Angeles, CA – May 17, 2016 - Albumedix and Hebei Changshan Biochem Pharma Co., Ltd (Changsan) today announced that they have entered into a supply agreement for the development of a novel type II diabetes treatment that enables once-weekly dosing. The agreement will see Albumedix’s recombinant albumin based half-life extension platform used for the development and later commercialization of a modified glucagon-like-peptide albumin conjugate (Albenatide) for the treatment of patients living with the condition in China.

 

According to the International Diabetes Federation, the Chinese diabetes population amounts to a staggering 114 million, representing a third of all people who have the condition worldwide. With a diabetes prevalence of 11.6 % for adults, China officially has the world’s largest diabetes epidemic. By combining Albumedix’s albumin-based drug delivery technology with Changsan’s clinical development expertise, Albenatide has the potential to extend the dosing frequency required by diabetics from daily to weekly, thereby significantly improving patient quality of life and treatment adherence as well as overall treatment cost.

 

Changshan operates through a joint venture with Los Angeles based ConjuChem LLC for the development of long-acting diabetic treatments.

 

“The collaboration between ConjuChem and Changsan is focused on the development of diabetes therapies for the Chinese market and we are currently in a Phase I clinical trial with Albenatide with the aim of moving into phase II later this year”, said Dr. Patrick Soon-Shiong, Chairman and CEO, ConjuChem, LLC and NantWorks, LLC. “ConjuChem created the Drug Affinity Complex (DACTM) which uses recombinant human albumin to improve a drug’s therapeutic index. We are confident that working with Albumedix and their exciting albumin-based platform will enable us to reach our goal of developing a patient friendly, once-weekly diabetes treatment.”

 

“China currently has the largest diabetes population in the world. Through the collaborations with ConjuChem and Albumedix, we are confident that we will be able to develop a more efficacious, safer and easier to use anti-diabetes medicine which will be a significant benefit to Chinese patients”, said Mr. Shuhua Gao, Chairman and General Manager of Changshan Biochem Pharma.

 

 

Albumedix albumin-based drug delivery platform, known as VELTIS®, is a platform of native and engineered recombinant human albumins. When combined with a drug candidate, it offers the potential for adaptive control of therapeutic half-life. The platform can significantly improve the treatment options available to diabetes patients by maintaining the therapeutic activity for prolonged periods, opening the door towards extended dosing intervals and improved quality of life.

 

“The adoption of Albumedix recombinant albumin products by Changshan is yet another example of how our albumin-based solutions can help alleviate some of the many complications faced daily by patients living with chronic diseases such as diabetes”, comments Peter Rosholm, CEO, Albumedix.

 

This agreement comes only a few months after the US market authorization of CSL Behring’s Idelvion®, a once-every-14-day hemophilia B treatment, which also utilizes Albumedix’s albumin-based technology.

 

“Like Idelvion, Albenatide further demonstrates the clinical and market value of our albumin-based platform”, adds Peter Rosholm.

 

This agreement will not impact the 2016 financial forecast for Albumedix’s parent company, Novozymes.

 

For further information on Albumedix’s VELTIS drug delivery platform, read more Here

 

About Albumedix

Albumedix improves patient outcome with a range of albumin-based products and technologies that facilitate the development of superior biotherapeutics.

 

Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years’ experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and fully owned subsidiary of Novozymes.

For further information please visit www.albumedix.com

 

About Hebei Changshan Biochem Pharma Co., Ltd

Hebei Changshan Biochem Pharma Co. Ltd. Is a Chinese public company (SZ300255), headquartered in Zhengding, Shijiazhuang, China. It is a leading producer specializing in developing, manufacturing and marketing heparin sodium, low molecular weight heparin (Enoxaparin, Dalteparin, Nadroparin). In 2013, Changshan through a joint venture partners with ConjuChem LLC to co-develop potential long-acting anti diabetes medicines for Chinese diabetes patients.

 

About Conjuchem LLC

ConjuChem, LLC is a privately biotechnology company with a corporate office located in Los Angeles, California. ConjuChem is owned by NantWorks, LLC. ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™). When applied to a given peptide, DAC™ and PC- DAC™ can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.

 

 

Contacts:

 

Albumedix

Jonas Skjødt Møller

jsqm@albumedix.com

+45 4446 2227

+45 3077 2227

 

Press Contact

Michelle Valentine

Discovery PR

michelle@discovery-pr.com

+44 (0)1606 889194+44 (0)1606 889194

 

 

 

SEND ME MORE...

Send now

Brochures

articles

Albumedix

Next event

The International yeast meeting

Meet up with Albumedix at the 2017 The International yeast meeting